Can cosentyx be used for pediatric psoriasis?

Can Cosentyx treat pediatric psoriasis?

Cosentyx is approved for children six years and older with moderate to severe plaque psoriasis. The FDA gave approval in 2021 based on two clinical studies that showed significant skin clearance.

What age groups show the best results?

The approval covers ages six and up. Studies included children from six through seventeen. Results showed PASI 75 scores reached 80 percent or higher in treated children compared with 11 percent in the placebo group.

What happens if a child receives early treatment?

Early treatment may prevent long-term skin damage and psychological effects from chronic psoriasis. Studies did not track long-term outcomes beyond the study period.

Why are companies challenging this patent?

Novartis holds patents covering secukinumab, the active ingredient in Cosentyx. Generic manufacturers have filed abbreviated new drug applications seeking approval before patent expiry. Companies challenge patents to enter the market as early as 2025 if courts rule in their favor.

How does this drug compare with other biologic treatments?

Cosentyx blocks IL-17A, a cytokine driving inflammation in psoriasis. Enbrel and Humira target TNF-alpha instead. Cosentyx shows higher skin clearance rates in pediatric trials compared with older TNF inhibitors.